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Background: Chemotherapy-induced nausea and vomiting
can adversely affect patients’ health and quality of life.
Guidelines recommend prophylactic antiemetic regimens
according to the emetogenic potential of anti-tumor thera-
pies. However, these recommendations are not for patients
receiving high-dose myeloablative regimens prior to stem
cell transplant (SCT). Current guidelines do not recommend
a speciﬁc antiemetic regimen for patients receiving high-
dose chemotherapy prior to SCT due to a lack of evidence. At
VCUHS, the standard of care in patients receiving high-dose
melphalan prior to SCT was an antiemetic regimen con-
sisting of ondansetron + dexamethasone. Due to perceived
poor nausea and vomiting control, the standard of care was
changed in August of 2012 to a three-drug regimen con-
taining aprepitant. Following this change in practice, this
project was undertaken for the primary objective of deter-
mining the effectiveness of an antiemetic regimen con-
taining aprepitant compared to the previous standard of
care in patients receiving high-dose melphalan prior to
autologous SCT.
Methods: This retrospective observational review compared
patients who received the previous antiemetic standard of
care to those who received the three-drug regimen con-
taining aprepitant prior to autologous SCT with high-dose
melphalan conditioning at VCUHS between April 2010
and April 2013. The primary outcome measure was
overall nausea control (NC), deﬁned as no episodes of
documented emesis and  2 uses of rescue antiemetics in
the overall phase (D-2 to D+2) with no additional scheduled
antiemetics.
Results: 114 patients were included in the analysis. The rate
of overall NC was not signiﬁcantly different between the
two groups [treatment difference -1%, 95% CI -19 to 18].
However, the mean number of episodes of emesis was
signiﬁcantly lower in the aprepitant group than in the
control group in the acute (0 vs. 0.2, p ¼ 0.012), delayed
(0.3 vs. 1.3, p < 0.001), and overall period (0.3 vs. 1.4, p <
0.001). Also, fewer patients in the aprepitant group
required additional scheduled antiemetics (3% vs. 36%, p ¼
0.011) than patients in the control group. There were no
signiﬁcant differences in length of stay or time to neutro-
phil engraftment.
Conclusions: The addition of aprepitant failed to demon-
strate a statistically signiﬁcant beneﬁt in terms of overall
NC when compared to the previous antiemetic standard of
care in patients receiving high-dose melphalan prior to
autologous SCT. This lack of beneﬁt and lower than ex-
pected rates of overall NC were attributed to aggressive
pre-emptive rescue antiemetic use and additional doses of
scheduled ondansetron in the control group. However, this
analysis did ﬁnd that aprepitant reduces episodes of
emesis and use of additional scheduled antiemetics in
patients receiving high-dose melphalan prior to autolo-
gous SCT.452
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Introduction: Cytomegalovirus (CMV) infection can increase
the morbidity and mortality associated with allogeneic he-
matopoietic stem cell transplantation (HSCT). Due to a higher
degree of immunosuppression, haploidentical transplants
can be at an increased risk of viral infections, particularly
CMV.
Methods: In a retrospective review of haploidentical HSCT
patients, we compared a traditional antiviral prophylaxis
regimen with an intensiﬁed approach to determine whether
a more intensive strategy could decrease rates of CMV
reactivation. CMV reactivation rates between the two groups
were compared using Fischer’s exact test. Themedian time to
reactivation and engraftment were compared using the
Mann-Whitney U test. A Kaplan-Meier survival curve was
utilized for non-relapse mortality (NRM) and patient groups
were compared using the log-rank statistic.
Results: A total of 84 patients underwent haploidentical
HSCT from 3/2009 through 5/2013. Patients were excluded
due to the following: donor and recipient negative serostatus
(n¼7), CMV reactivation prior to day 0 (n¼3), second trans-
plant (n¼7), or use of other antiviral therapy during the ﬁrst
100 days for non-CMV infections (n¼4). The median follow
up for the remaining 63 patients was 295 days (range 7 e
1473). Patients received valacyclovir 500 mg orally daily
starting on day -1 (n¼26) or either valganciclovir 900 mg
orally twice a day or ganciclovir 5 mg/kg IV twice daily from
admission through day -2 followed by traditional or high
dose valacyclovir (n¼37). Upon CMV reactivation, preemp-
tive therapy was commenced in both groups. Baseline char-
acteristics were similar between the groups and all patients
received conditioning chemotherapy with ﬂudarabine and
melphalan +/- TBI 200 cGy or thiotepa, as previously
described. CMV reactivation prior to day 100 was lower in
the intensive strategy group compared to the traditional
strategy although not signiﬁcant (68% vs. 85%; p¼ 0.15).
Median time to CMV reactivation was not signiﬁcant be-
tween the traditional and intensive groups (31 days vs. 33
days; p ¼0.13). A difference in median time to engraftment
was not evident (18 days vs. 18 days; p¼0.72). One patient in
each group had primary graft failure. Non-relapse mortality
did not differ between the groups [HR 0.75 (0.25, 2.22);
p¼0.6].
Conclusion: A trend towards decreased CMV reactivation and
longer time to reactivation was seen with an active CMV
regimen prior to day 0 in haploidentical HSCT patients.
Although currently underpowered, data collection is ongoing.453
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Purpose: Calcineurin inhibitors are used to prevent graft
versus host disease in allogeneic stem cell transplant re-
cipients. Achieving therapeutic drug levels prior to trans-
plant engraftment decreases the development of graft versus
host disease. The objective of this study is to investigate if
higher initial dosing of calcineurin inhibitors results in a
shorter time to therapeutic drug levels.
Methods: This study, approved by the Institutional Review
Board, is a retrospective chart review comparing two dosing
strategies of cyclosporine and tacrolimus. The following data
was collected: patient age, gender, ethnicity, initial dose of
cyclosporine or tacrolimus, time to therapeutic drug levels,
time to engraftment, change in bilirubin, and change in
serum creatinine. All data was recorded without patient
identiﬁers and maintained conﬁdentially. Data will be
divided into a low initial dosing group and a high initial
dosing group and time to therapeutic drug levels will be
compared. Descriptive statistics will be utilized to compare
starting doses of calcineurin inhibitors and time to thera-
peutic drug levels.
Conclusion: If correlation is shown, allogeneic stem cell
transplant recipients may be able to reach therapeutic drug
levels sooner and further prevent graft versus host disease
which would decrease mortality and morbidity in this high
risk population. Assessment of this dosing protocol may lead
to more aggressive and individualized dosing strategies.454
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High-dose cyclophosphamide (Cy) is a common component
of conditioning regimens that patients receive prior to he-
matopoietic cell transplant (HCT). Due to concerns for
increased risk of toxicity, obese patients at Virginia
Commonwealth University Health System (VCUHS) receive
doses of Cy based on an adjusted body weight (ABW; ABW ¼
[(total body weight [TBW] e ideal body weight [IBW]) x 0.4]
+ IBW) whereas non-obese patients receive doses based on
TBW. However, these practices are inconsistent with the
American Society of Clinical Oncology (ASCO) 2012 guide-
lines, which recommend that obese patients receive full-
dose chemotherapy. Interestingly, these guidelines excluded
patients with hematological malignancies undergoing HCT
from their literature review. Using a retrospective medical
record review, we examined whether there is a difference in
effectiveness and toxicity between obese and non-obese
patients who receive high-dose Cy prior to HCT.
The primary objective of this study was to determine if there
is a difference in toxicity between obese versus non-obese
patients during the ﬁrst 60 days following transplant.
Toxicity was measured as a composite endpoint of overall
toxicity, which was comprised of any grade 3 or 4 non-he-
matological toxicity, the incidence of pulmonary, hepatic,
renal, or cardiac toxicity, and each component individually.Secondary objectives were to compare the differences in
effectiveness between obese and non-obese patients
assessed by relapse at day +100, relapse at one year, death at
one year, chimerisms at days +30, +60, and +90, and the
incidence of acute graft versus host disease (aGVHD).We also
sought to evaluate the difference in time to engraftment and
rates of infection between groups. Chi-squared test and
Fisher’s exact test were used to assess the primary and sec-
ondary endpoints and two-sample t-tests were used to
assess time to engraftment.
Sixty-one patients met the inclusion criteria. Of these, 28
were considered to be obese while 33 were considered to be
non-obese. Mean BMI was 24.7  2.5 in non-obese patients
and 32.5  4.3 in obese patients. The mean Cy dose in non-
obese and obese patients was 56.80  10.4 mg/kg and 48.55
 3.3 mg/kg of TBW, respectively. The rate of overall toxicity
was greater in the obese patients compared to non-obese
patients (82% vs 52%, OR 4.3 [95% CI 1.3-14.1]), which was
driven by a signiﬁcantly greater incidence of renal dysfunc-
tion (79% vs 48%, OR 3.9 [95% CI 1.3-12.1]). There were no
differences in rates of grade 3 or 4 toxicity, hepatic
dysfunction, or any measure of effectiveness between
groups. Although obese patients are at increased risk of
toxicity, they appear to achieve the same effectiveness as
non-obese patients. Since the increased risk of toxicity is due
to increases in grade 2 renal toxicity, there is no evidence to
support changing the dosing practices at VCUHS.455
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High dose IV melphalan is widely used in preparative regi-
mens for hematopoietic cell transplantation. Package insert
recommendations state to prepare doses to a concentration
of </¼ 0.45 mg/mL in Normal Saline (NS) and to infuse
within 60 minutes of reconstitution. When using these rec-
ommendations, many doses must be prepared in volumes of
1000 mL or more which results in infusion rates of up to 2
liters/hour over 30 minutes. Available infusion pumps have
maximum infusion rate of 999 mL/hour, often requiring
doses be prepared in multiple bags and infused simulta-
neously using 2 pumps to ensure a 30 minute infusion time.
Melphalan was found to have 90% or greater stability at 60
and 90 minutes when diluted in NS polyoleﬁn bags to con-
centrations from 0.45 mg/mL to 2 mg/mL e personal
